BRPI0814471A2 - Preparação de anticorpo, método para produzir a preparação de anticorpo, composição farmacêutica, kit de partes, e, uso de uma preparação de anticorpo - Google Patents

Preparação de anticorpo, método para produzir a preparação de anticorpo, composição farmacêutica, kit de partes, e, uso de uma preparação de anticorpo

Info

Publication number
BRPI0814471A2
BRPI0814471A2 BRPI0814471-0A2A BRPI0814471A BRPI0814471A2 BR PI0814471 A2 BRPI0814471 A2 BR PI0814471A2 BR PI0814471 A BRPI0814471 A BR PI0814471A BR PI0814471 A2 BRPI0814471 A2 BR PI0814471A2
Authority
BR
Brazil
Prior art keywords
antibody preparation
pharmaceutical composition
producing
parts kit
preparation
Prior art date
Application number
BRPI0814471-0A2A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Paul Andrew Hamblin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0814471A2 publication Critical patent/BRPI0814471A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0814471-0A2A 2007-08-01 2008-07-28 Preparação de anticorpo, método para produzir a preparação de anticorpo, composição farmacêutica, kit de partes, e, uso de uma preparação de anticorpo BRPI0814471A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95321007P 2007-08-01 2007-08-01
PCT/EP2008/059900 WO2009016164A1 (en) 2007-08-01 2008-07-28 Novel antibodies

Publications (1)

Publication Number Publication Date
BRPI0814471A2 true BRPI0814471A2 (pt) 2015-02-03

Family

ID=40029299

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814471-0A2A BRPI0814471A2 (pt) 2007-08-01 2008-07-28 Preparação de anticorpo, método para produzir a preparação de anticorpo, composição farmacêutica, kit de partes, e, uso de uma preparação de anticorpo

Country Status (11)

Country Link
US (1) US20110262430A1 (pt)
EP (1) EP2190879A1 (pt)
JP (1) JP2010534710A (pt)
KR (1) KR20100057021A (pt)
CN (1) CN101855244A (pt)
AU (1) AU2008281801A1 (pt)
BR (1) BRPI0814471A2 (pt)
CA (1) CA2694055A1 (pt)
EA (1) EA201000053A1 (pt)
MX (1) MX2010001237A (pt)
WO (1) WO2009016164A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
AR074726A1 (es) 2008-12-12 2011-02-09 Boehringer Ingelheim Int Anticuerpos anti-igf (factor de crecimiento insulinico)
CN102666874B (zh) 2009-10-07 2016-06-01 宏观基因有限公司 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
JP2015505843A (ja) * 2011-12-15 2015-02-26 ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用
WO2013106603A1 (en) * 2012-01-10 2013-07-18 Expression Pathology, Inc. Srm/mrm assay for the insulin receptor protein
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
SG11201602979RA (en) * 2013-10-17 2016-05-30 Univ Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
EA037749B1 (ru) * 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
JP6959229B2 (ja) * 2015-10-23 2021-11-02 アポジェニックス アーゲー 一本鎖ｇｉｔｒ受容体アゴニストタンパク質
US20250027945A1 (en) * 2021-08-18 2025-01-23 The Regents Of The University Of California Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
AU2005269759A1 (en) * 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
EP1871808A2 (en) * 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2007039818A2 (en) * 2005-05-09 2007-04-12 Glycart Biotechnology Ag Antigen binding molecules having modified fc regions and altered binding to fc receptors
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
WO2008098115A2 (en) * 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same

Also Published As

Publication number Publication date
CA2694055A1 (en) 2009-02-05
KR20100057021A (ko) 2010-05-28
AU2008281801A1 (en) 2009-02-05
MX2010001237A (es) 2010-03-01
EA201000053A1 (ru) 2010-08-30
JP2010534710A (ja) 2010-11-11
WO2009016164A1 (en) 2009-02-05
US20110262430A1 (en) 2011-10-27
EP2190879A1 (en) 2010-06-02
CN101855244A (zh) 2010-10-06

Similar Documents

Publication Publication Date Title
BRPI0814471A2 (pt) Preparação de anticorpo, método para produzir a preparação de anticorpo, composição farmacêutica, kit de partes, e, uso de uma preparação de anticorpo
BRPI0814611A2 (pt) Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0918359A2 (pt) composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0813306A2 (pt) composto, composição farmacêutica, método para produzir a inibição de uma cisteína protease em um mamífero, e, uso de um composto.
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0919192A2 (pt) Uso de lipídio, composição nutricional, e, processo para a produção de uma composição nutricional
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0907186A2 (pt) Composições proteicas pulverizadas e métodos para sua produção
BRPI0819936A2 (pt) Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação.
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI0816513A2 (pt) Composição farmacêutica e método para preparar a suspensão sólida
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0814503A2 (pt) composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI0817182A2 (pt) Método para purificar um anticorpo e composições
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0818680A2 (pt) composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
BRPI0807536A2 (pt) Processos para a preparação do composto, e para a preparação de uma mistura, e, uso de uma mistura
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0821600A2 (pt) Composição farmacêutica, artigo de fabricação, kit de partes, método de combater aterosclerose, ou uma doença cardiovascular associada à aterosclerose, e, uso de um anticorpo
BRPI0918487A2 (pt) processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.